Effect of renin-angiotensin system inhibitor on long-term prognosis after contrast-associated acute kidney injury in patients with coronary heart disease
DOI:
Author:
Affiliation:

1.Department of Cardiology, Guangdong Provincial People's Hospital & Guangdong Institute of Cardiovascular Disease & Guangdong Key Laboratory of Coronary Heart Disease Prevention, Guangzhou, Guangdong 510080, China;2.Department of Pharmacy, Zhaoqing First People's Hospital, Zhaoqing, Guangdong 526000, China)

Clc Number:

R54

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Aim To investigate the effect of renin-angiotensin system inhibitor (RASI) on long-term prognosis in patients with coronary heart disease (CHD) after contrast-associated acute kidney injury (CA-AKI). Methods A total of 1 526 patients with CHD diagnosed by coronary angiography and postoperative CA-AKI in Guangdong Provincial People's Hospital from January 2008 to December 2018 were included in this study. They were divided into RASI group (n=984) and non-RASI group (n=542) according to whether they took RASI or not. The primary end point was long-term all-cause death. Baseline clinical data were compared between the two groups. Kaplan-Meier method and COX regression analysis were used to evaluate the effect of RASI on long-term prognosis. Results The proportion of β-receptor blockers and statins used in the RASI group was higher than that in the non-RASI group (P<0.01). During the median follow-up period of 4.75 years (quartile 2.82 years, 6.67 years), 332 patients died, and the all-cause mortality was 21.76%. Kaplan-Meier survival analysis showed that the mortality of RASI group was lower than that of non-RASI group (P=0.001). Univariate and multivariate COX regression analysis showed that RASI treatment after discharge was significantly negatively correlated with all-cause death (P=0.001, P=0.034), and RASI was an independent protective factor for long-term all-cause death. Conclusions RASI is an independent protective factor for the long-term prognosis of CHD patients after CA-AKI. Long-term use of RASI therapy can reduce the all-cause death in patients with CHD and CA-AKI.

    Reference
    Related
    Cited by
Get Citation

WANG Bo, YANG Xuxi, HUANG Xiuqiong, CHEN Shiqun, LIU Yong, TAN Ning. Effect of renin-angiotensin system inhibitor on long-term prognosis after contrast-associated acute kidney injury in patients with coronary heart disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(11):977-982.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 07,2020
  • Revised:December 29,2020
  • Adopted:
  • Online: November 18,2021
  • Published:
Article QR Code